Clinical trial
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without…
NCT00070278 · Cambridge University Hospitals NHS Foundation Trust, Other · Unknown status
Key facts
| NCT number | NCT00070278 |
|---|---|
| Title | Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer |
| Official title | A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphamide and Paclitaxel + - Gemcitabine in Poor Risk Early Breast Cancer |
| Lead sponsor | Cambridge University Hospitals NHS Foundation Trust, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Genetic, Procedure |
| Interventions | cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride, paclitaxel, comparative genomic hybridization, microarray analysis, mutation analysis, conventional surgery, neoadjuvant therapy |
| Enrollment | 800 |
| Start date | Jan 1, 2005 |
| Primary completion | Sep 1, 2007 |
| First posted | Oct 7, 2003 |
| Last update posted | Aug 7, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: